Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × LY3022855 × Clear all

Phase

Phase 1 2 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 358 Cyclophosphamide 346 Carboplatin 278 Paclitaxel 252 Gemcitabine 250 Nivolumab 245 Cisplatin 220 Radiotherapy 202 Bevacizumab 185 Dexamethasone 179 Docetaxel 170 fludarabine 164 Rituximab 159 Capecitabine 148 Lenalidomide 140 Oxaliplatin 134 Fluorouracil 131 Temozolomide 127 Cytarabine 119 Irinotecan 113 Etoposide 111 Cetuximab 110 venetoclax 107 fludarabine phosphate 107 Doxorubicin 103 Injections 102 Ipilimumab 98 130-nm albumin-bound paclitaxel 98 Azacitidine 96 Prednisone 94

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute

Phase 1/2 Completed

5 enrolled 10 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡